Robert Reiter, MD Robert Reiter, MD
Conditions
Procedures

Robert E. Reiter, M.D., M.B.A

 

 

Department of Urology                                                            Office: (310)-794-7224

David Geffen School of Medicine at UCLA              Fax: (310)-206-5343

Center for the Health Sciences, Room 66-128              Lab: (310)-206-5942

10833 Le Conte Ave.                                                     rreiter@mednet.ucla.edu

Los Angeles, CA. 90095-1738

 

Professional

 

1996-2000            Assistant Professor of Urology, UCLA School of Medicine, Los Angeles, CA

1998-present        Associate Director, Prostate Cancer Program Area, Jonsson  Comprehensive Cancer Center, Los Angeles, CA

2000-2004           Associate Professor of Urology, UCLA School of Medicine, Los Angeles, CA

2001- present     Director of Research, Department of Urology, UCLA School of Medicine,

Los Angeles, CA

2002-present       Member, Molecular Biology Institute

2004-present       Professor of Urology, UCLA School of Medicine, Los Angeles, CA

2006-present     Director, Genitourinary and Prostate Cancer Program, Jonsson Comprehensive Cancer Center, Los Angeles, CA

2006-present     Director, Prostate Cancer Treatment and Research Program, UCLA School of Medicine

2007-present     Founder and Chief Medical Office, ImaginAb Corporation, Culver City, CA

2008-present     Founder, EMTx Therapeutics, Los Angeles, CA

 

 

Education

                                   

1983          B.S., Yale University, New Haven, CT, magna cum laude in Biology

1988     M.D., Stanford University School of Medicine, Stanford, CA

2007     M.B.A., Anderson School of Management, UCLA, Los Angeles, CA.                                                   

 

Residency

 

1988-1989                     Stanford University                  Internal Medicine            Intern

1989-1990                     Stanford University                  General Surgery            Resident

1990-91, 1993-94         Baylor College of Medicine            Urology                        Resident

1994-1995                     Baylor College of Medicine            Urology                        Chief Resident

 

Fellowships

 

1991-1993            Clinical Associate, Urologic Oncology, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD (laboratory of Dr. Marston                  Linehan)                      

1995-1996                        Clinical Instructor, UCLA Department of Urology (laboratory of Dr. Owen Witte)

 

Awards and Honors

 

1983-1984            Fulbright Scholar, Barcelona, Spain

1995-1997            UCLA Jonsson Comprehensive Cancer Center Young Investigator Development Award

1996-1999            STOP Cancer Young Investigator Award

1997-1999                 Edwin Beer Award of the New York Academy of Medicine

1997-2002            Physician-Scientist Award, National Cancer Institute

1996-2001            Cap Cure Research Award

2000                 American Urologic Association/European Association of Urology Academic                                 Exchange Fellow

2002-2003                 Innovator in Urology

2004                    Election into American Society for Clinical Investigation

2004                 Young Investigator Award of the Society of Urologic Oncology (given to the urologist who has contributed most to translational research in urology within ten years of completing residency training)

 

 

Current Appointments

 

1995-present            Attending Urologist, UCLA Center for the Health Sciences, Los Angeles, CA

1995-present            Attending Urologist, Wadsworth Veterans Affairs Medical Center, Los Angeles,                                   CA      

 

UNIVERSITY SERVICE

 

1995-present            Coordinator, Prostate Cancer Journal Club, Jonsson Comprehensive Cancer                                     Center

1995-present            Coordinator, Prostate Cancer Seminar Series, Jonsson Comprehensive Cancer                                     Center

1997                 Prostate Cancer Research Faculty Search Committee

1997-present            UCLA Biosafety Committee

1997-present            UCLA Seismic Staging Facility #2 Planning Committee

1997-present            Seed Grant Reviewer, Jonsson Comprehensive Cancer Center

1998-present            Cancer Committee

1998-present     Associate Director, Genitourinary Cancer Program Area, Jonsson Comprehensive Cancer Center, Los Angeles, CA

2001- present            Director of Research, Department of Urology, UCLA School of Medicine,

                         Los Angeles, CA

2002 -present    Advisory Board, Tedd Mann Family Resource Center, Jonsson Comprehensive Cancer Center

2003- present            Executive Committee, Department of Urology

2003-present            Tissue Procurement Committee

2007-present            Clinical Trials Quality Assurance Committee

 

OTHER SERVICE

 

Study Sections

 

1997-1999                 Ad Hoc Study Section, American Cancer Society, California Division

1998-2000         Department of Defense Prostate Cancer Research Program

1999-2002          CapCURE

2000                           Ad Hoc Study Section, NIDDK, NIH

2004                 Ad Hoc Study Section, NCI, NIH

2003                                  Department of Defense Prostate Cancer Research Program

2008                 Department of Defense Prostate Cancer Research Program  Integration Committee

 

Reviewer

 

1995-present            Journal of Urology

1998-present            Journal of the National Cancer Institute

1998-present            American Journal of Pathology

1998-present            Urology

1999-present            The Prostate

2000-present            International Journal of Cancer

2000-present            Editorial Board, Prostate Cancer and Prostatic Diseases

2000-present            Cancer Letters

2000-present            Cancer Research

2001-present              Journal of Clinical Oncology

2001-present            Oncology

2002-present     Editorial Board, The American Journal of Urology Review

2003-present            Clinical Cancer Research

 

Consulting

 

1996-2002                 Agensys, Santa Monica, CA (Founding Scientist)

2002-present    Council of Advisors, Gerson Lehrman Consulting Group

1999-2004         Astra Zeneca

2003-present     Amgen

2003-present      Abbott Pharmaceuticals

2004                                  Corixa Corporation

2007-present            Tokai

2007-present            Takeda Corporation (sponsored research and consulting)

2008-present            Astra Zeneca

2007-present            ImaginAb, Culver City, CA (Founder)

2008-present            UroTech Corporation

2008-present            EMTx Therapeutics (Founder)         

 

Other

2002-2005         Co-Chairman, Clinical Trial Scientific Advisory Board, NCI Prostate SPOREs

 

Professional Organizations

 

1988-present            American Medical Association

1994-present            American Urological Association

1996-present            Los Angeles Urological Society—Secretary-Vice President

1998-present            Western Section, American Urological Association

2000-present            American Association for Cancer Research

2001-present            Society for Basic Urologic Research

2002-present            Society for Urologic Oncology

2003                          President, Los Angeles Urological Society

 

Teaching: Postdoctoral, Resident and Graduate Students

 

1998-1999            Eric Torgerson, M.D.

1997-2001            Zhennan Gu, Ph.D. (Assistant Professor, Wake Forest Univ)

2000-2001            Jin-Hee Lee, M.D.

2001-2002                 Ganesh Palapattu, M.D. (Assistant Professor, Univ. of Rochester)

1999-2003            Chau Tran, Ph.D. (Assistant Researcher, UCLA)

2000-2002            Anjali Jain, Ph.D. (Assistant Professor, UCLA)

2002-2003            Isla Garraway, M.D., Ph.D (Assistant Professor, UCLA)

2003                       Jay Barry, Ph.D Candidate

2003-2004            Haoquan Wu, Ph.D.

2003                      Jonathan Chin, M.D.

2005                       Herve Wallebrand, M.D. (Assistant Professor, University of Paris)

2007                        Ben Shurtleff, M.D.

2006-7                                          Isla Garraway, M.D. Ph.D (Assistant Professor, UCLA)

2008-present            Corina Sarmiento, Ph.D

2008-present            Yulia Khodovorsky PhD

 

                       

 

Licenses and Certification

 

1988                 Diplomate, National Board of Medical Examiners

1989-present            State of California (#G67515)

1995-present            DEA (# BR4630148)

1998-present             American Board of Urology

 
 
 
 
Active Funded Peer-reviewed Research Grants

 

1. National Cancer Institute. Specialized Program of Research Excellence (SPORE) in Prostate Cancer            9/07-8/12

Principal Investigator: Robert E. Reiter, M.D.

Co-Principal Investigators: Jean B. dekernion, M.D.

Amount: $13,279,556 (Direct + Indirect Costs)

 

Project 1: Engineered PSCA Antibodies for Molecular Imaging of Prostate Cancer

Principal Investigator: Robert E. Reiter, M.D. and Anna Wu, Ph.D.

Amount: $800,000 (Direct Costs)

 

2. Department of Defense Army Research Grants (Award # pending) 1/08-1/11

            Title: Engineered antibodies for PSCA targeted imaging of prostate cancer

            Principal Investigator: Robert E. Reiter, M.D.

            Co-Investigator: Anna Wu, Ph.D

            Amount: $1,100,000 (Direct + Indirect Costs)

 

3.  Department of Defense Army Research Grants (Award #  PC 050896 ) 1/6-1/09

            Title: Mechanism of Action of PSCA Targeted Antibody Therapy

            Principal Investigator: Robert E. Reiter, M.D.

            Amount: $570,000 (Direct + Indirect Costs)

 

4. Department of Defense Army Research Grants (Synergy Award # PC) 1/09-1/12

            Title: N-cadherin in Prostate Cancer

            Principal Investigator: Robert E. Reiter, M.D.

Co-Investigator: Matthew Rettig, M.D.

            Amount: $1,100,000

 

5. Takeda Pharmaceutical Company (1/07-1/10)

            Title: Epithelial to Mesechymal Transition Targets in Prostate Cancer

            Principal Investigator: Robert E. Reiter, M.D.

            Amount: $600,000 (Direct Costs)

 

6. Prostate Cancer Foundation (6/07-6/08)

            Title: EMT in prostate cancer

            Principal Investigator: Robert E. Reiter, M.D.

            Amount: $50,000 (Direct Costs)

 

           

Active Grants for Trainees in the Reiter Lab
 

Isla Garrway: New Investigator Award, Department of Defense, 2006-2009, $360,000

Zev Wainberg: Physician Scientist Award, Department of Defense, 2006-2010, $500,000

Hideyo Miyazaki: Seed Grant, Jonsson Cancer Center UCLA, 2005-2006, $30,000

Aram Armenian: Howard Hughes Medical Student Research Fellowship, 2005-2006, $30,000Chau Tran: Young Investigator Award, Prostate Cancer Foundation 2008  $50,000

 

Inactive Research Grants

 

1. National Institutes of Health (K08 CA741690)            7/1/97-6/30/02

            Title: Markers of Androgen-Independent Prostate Cancer

            Prinicipal Investigator: Robert E. Reiter, M.D.

            Amount: $401,790  

 

2. Cancer Research Institute, Inc. (Award # 018009)   7/1/98-6/30/01

            Title: Structural and functional characterization of prostate stem cell antigens.

            Co-Principal Investigators: Robert E. Reiter and Owen N. Witte

            Amount: $300,000 (Direct Costs)

 

 

3.   Department of Defense Army Research Grants (Award # DAMD17-98-1-8578) 10/98-4/01

            Title: A Transgenic Stem Cell Model of Prostate Cancer

            Principal Investigator: Robert E. Reiter

            Amount: $391,129 (Direct Costs)

 

4.  STOP Cancer Foundation          7/1/96-6/30/99

            Amount: $150,000 (Direct Costs)

 

5.   New York Academy of Medicine Edwin Beer Award          9/1/97-8/30/99

            Title: Identification of Biological Markers in Androgen-Independent Prostate                                    Cancer

               Prinicipal Investigator: Robert E. Reiter, M.D.

            Amount: $75,000 (Direct Costs)

 

6. Jonsson Cancer Center Foundation  8/1/96-7/30/99      

            Title: Molecular Basis for Prostate Cancer Progression                              

            Co-Prinicipal Investigators: Charles L. Sawyers, M.D., Robert E. Reiter, M.D.                             Jay Lieberman, M.D.

            Amount:  $450,000 (Direct Costs)

 

7.   CaP CURE Genetics Consortium            1/1/95-12/98

            Title: Prostate Cancer Genomics

            Co-Principal Investigators: Owen N. Witte, M.D., Robert E. Reiter, M.D., and                               Charles L. Sawyers, M.D.

            Amount: $200,000 (Direct Costs)

 

8. Cancer Research Coordinating Committee, University of California  7/96-6/97

            Title: Markers of Androgen-Independent Prostate Cancer

            Principal Investigator: Robert E. Reiter, M.D.

            Amount: $30,000 (Direct Costs)

 

9. Jonsson Comprehensive Cancer Center Young Investigator Award    7/95-6/97

            Principal Investigator: Robert E. Reiter, M.D.

            Amount: ~$90,000 (Direct Costs)

 

10. Carolan Foundation Prostate Cancer Seed Grant   7/96-6/97

            Title: Chromosome 12p in Prostate Cancer

            Principal Investigator: Robert Reiter, M.D.

            Amount: $25,000 (Direct Costs)

 

11. CaP CURE  1/1/97-12/01

            Title: Prostate stem cell antigen: a novel prostate-specific, cell surface target                            for prostate cancer diagnosis and treatment

            Principal Investigator: Robert E. Reiter, M.D.

            Amount: $450,000 (Direct Costs)

 

12. National Institutes of Health (R01 DK52673)    3/27/98-2/28/02

            Title: Stem cell genes in human prostate growth and differentiation.

            Co-Principal Investigators: Robert E. Reiter, M.D. and Charles L. Sawyers, M.D.

            Amount: $669,047 (Direct Costs)

 

13.  Department of Defense Army Research Grants (Award # PC 001588) 7/01-6/04

            Title: Prostate Stem Cell Antigen: A Promising Prognostic Marker in Prostate Cancer

            Principal Investigator: Robert E. Reiter, M.D.

            Amount: $410,732 (Direct Costs)

 

14. National Institutes of Health--Program Project Grant  (RFA CA-98-013) 9/99-9/04

            Title: Mouse Models of Prostate Cancer

            Principal Investigator: Charles Sawyers, M.D.

            Co-Investigator: Robert E. Reiter

            Amount: $2,500,000 (Direct Costs)

 

15. Margaret Early Trust Research Grant   1/ 01-12/04

            Title: Development of a Transgenic Model of Prostate Cancer Using A Retroviral Gene-   Specific Transfer System

            Principal Investigator: Robert E. Reiter

            Amount: $150,000        

 

16. California Cancer Research Program             9/99-9/02

            Title: Quality of life in men with early stage prostate cancer.

            Principal Investigator: Mark Litwin

            Co-Investigator: Robert E. Reiter

                Amount: $648,043  (Direct Costs)

 

17.  Department of Defense Army Research Grants (Award #  PC 010083) 2/02-2/05

            Title: Mechanisms and Refinements of PSCA Directed Antibody Therapy

            Principal Investigator: Robert E. Reiter, M.D.

            Amount: $570,000 (Direct + Indirect Costs)

 

18. National Cancer Institute. Specialized Program of Research Excellence (SPORE) in Prostate Cancer            10/02-9/07

Principal Investigator: Jean B. deKernion, M.D.

Co-Principal Investigators: Robert E. Reiter, Charles L. Sawyers and Robert Elashoff

Amount: $13,279,556 (Direct + Indirect Costs)

 

Project 1: Preclinical and Clinical Studies of Prostate Stem Cell Antigen Monoclonal Antibodies

Principal Investigator: Robert E. Reiter, M.D.

Amount: $800,000 (Direct Costs)

 

19.   Department of Defense Army Research Grants (Award # PC 020234) 1/03-1/06                     

Principal Investigator: Robert E. Reiter, M.D.

Title: A PSCA Promoter Based Avian Retroviral (TVA) Transgenic Model for the Study of Normal and Malignant Prostate Disease

Amount: 559,250 (Direct+ Indirect Costs)

 

20.    American Cancer Society Research Scholar Grant   1/02-1/06         

            Title: Prosate stem cell antigen: Target for antibody therapy of prostate cancer

            Princicpal Investigator: Robert E. Reiter

            Amount: $746,000 (Direct)

 

21. Department of Defense Army Research Grants (Award # PC 001588) 1/05-1/08

            Title: Reg IV: a Promising Marker of Hormone Refractory Prostate Cancer

            Principal Investigator: Robert E. Reiter, M.D.

            Amount: $560,000 (Direct + Indirect Costs)

 

22. National Institutes of Health--Program Project Grant  (RFA CA-98-013) 9/04-8/09

            Title: Mouse Models of Prostate Cancer

            Principal Investigator: Charles Sawyers, M.D.

            Co-Investigator: Robert E. Reiter

            Amount: $2,500,000 (Direct Costs)

 

 

 

Publications In Refereed Journals

 

1. Marcus SG, Choyke PL, Reiter RE, Jaffe GS, Alexander RB, Linehan WM, Rosenberg SA, Walther MM:  Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy.  Journal of Urology 150:463, 1993

 

2. Makos M, Nelkin BD, Reiter RE, Gnarra JR, Brooks J, Isaacs W, Linehan WM, Baylin SB:  Regional DNA hypermethylation at D17S5 precedes 17p structural changes in the progression of renal tumors.  Cancer Research 53:2719, 1993  (Citations as of 10/99: 63)

 

3. Reiter RE, Anglard P, Liu S, Gnarra JR, Linehan WM:  Chromosome 17p deletions and p53 mutations in renal cell carcinoma.  Cancer Research 53:3092, 1993 (Citations as of 10/99: 54)

 

4. Reiter RE, Linehan WM:  Evaluating scrotal masses.  IM:  Internal Medicine 14:49, 1993

 

5. Walther MM, Choyke PL, Weiss G, Manalatos C, Long J, Reiter RE, Alexander RB, Linehan WM:  Parenchymal sparing surgery in patients with hereditary renal cell carcinoma.  Journal of Urology 153:913, 1995

 

6. Klein K*, Reiter RE*, Marada H, Redula J, Lin X, Brothman AR, Belldegrun A, Witte ON, Sawyers CL:  Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. (* indicates co-first authorship) Nature Medicine 3:402, 1997 (Citations as of 10/99: 18)

 

7. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, LeBeau MM, Loda M, Witte ON: Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proceedings of the National Academy of Sciences 95: 1735, 1998 (Citations as of 10/99: 11)

 

8. Yang RM, Naitoh J, Murphy M, Wang H-J, Phillipson J, deKernion JB, Loda M, Reiter RE: Low p27 expression predicts poor disease-free survival in patients with prostate cancer. Journal of Urology 159:941, 1998 (Citations as of 10/99: 31)

 

9. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said J, Isaacs WB, Sawyers CL: Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proceedings of the National Academy of Sciences 95: 5246, 1998 (Citations as of 10/99: 23)

 

10. Bui M, Reiter RE. Stem cell genes in androgen independent prostate cancer. Cancer and Metastasis Reviews, 17: 391-399, 1998-1999

 

11. Torgerson E, Dobkin B, Reiter RE. Myasthenia gravis as a paraneoplastic syndrome associated with renal cell carcinoma. Journal of Urology, 162:154, 1999

                       

12. Walther MM, Reiter RE, Keiser HR, Choyke PL, Venzon D, Hurley K, Gnarra JR, Reynolds JC, Glenn GM, Zbar B, Linehan WM:  Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. Journal of Urology, 162:659, 1999

 

13. Pflug B, Reiter RE, Nelson JB. Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines. The Prostate, 40: 269, 1999.

 

14. Craft N, Chhor C, Tran C, Belldegrun A, deKernion J, Witte ON, Said J, Reiter RE, Sawyers CL. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Research, 59: 5030, 1999.

 

15. Reiter RE. Prostate cancer diagnostics: obstacles and opportunities. Journal in Urology, 162: 2046, 1999.

 

16. Saffran DC, Reiter RE, Jakobovits A, Witte ON. Target antigens for prostate cancer immunotherapy. Cancer and Metastasis Reviews, 18: 437, 1999

 

17. Reiter RE, Sato I, Thomas G, Qian J, Watabe T, Loda M, Jenkins RB. Co-amplification of PSCA and c-myc in locally advanced prostate cancer. Genes Chromosomes and Cancer, 27: 95, 2000.

 

18. Brandeis JM, Litwin MS, Burnison CM, Reiter RE. Quality of life outcomes after brachytherapy for early stage prostate cancer. Journal of Urology, 163: 851, 2000.

 

19. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Raitano A, Witte ON, Said JW, Loda M, Reiter RE. Prostate stem cell antigen (PSCA) expression correlates with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene, 19: 1288, 2000.

 

20. Thomas GV, Schrage MI, Rosenfelt L, Kim JH, Salur G, deKernion JB, Dorey F, Said J, Reiter RE. Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, gleason grade and pathological stage. Journal of Urology, 164: 1987, 2000.

(editorial, pg. 1996)

 

21. Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A. Anti-PSCA monoclonal antibodies inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts.  Proceedings of the National Academy of Sciences, 98: 2658, 2001

 

22. Dubey P, Wu H, Reiter RE, Witte ON. Alternative pathways to prostate carcinoma activate PSCA expression. Cancer Research, 61: 3256,  2001.

 

23. Argani P, Rosty C, Reiter RE, Wilentz RE, Murugesan SR, Leach SD, Ryu B, Skinner HG, Goggins M, Jaffee EM, Yeo CJ, Cameron JL, Kern SE, Hruban RH. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Research, 61: 4320,  2001.

 

24. Amara N, Palapattu GS, Gu Z, Thomas GV, Schrage M, Dorey F, Said J, Reiter RE. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Research, 61: 4660, 2001.

 

25. Tsingotjidou AS, Zotalis G, Jackson K, Sawyers CL, Puzas EJ,  Hicks DG, Reiter RE, Lieberman JR. Development of an animal model for prostate cancer cell metastasis to adult human bone. Anticancer Research, 21: 971, 2001.

 

26. Watabe T, Lin M, Donjacour AA, Cunha G, Witte ON, Reiter RE. In situ visualization of a growth responsive subset of epithelial cells associated with prostate development, regeneration and tumorigenesis. Proceedings of the National Academy of Sciences, 99: 401, 2002

 

27. DePrimo SE, Diehn M, Nelson JB, Reiter RE, Matese J, Fero M, Tibshirani R, Brown PO and Brooks JD.  Transcriptional programs activated by exposure of human prostate cancer cells to androgen.  Genome Biology, 3: (June, online). 2002.

 

28. Jain A, Lam A, Vivanco I, Carey MF, Reiter RE. Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene.  Molecular Endocrinology, 16: 2323. 2002.

 

29. Palapattu G, Reiter RE. Monoclonal antibody therapy in urological malignancies. Journal of Urology, 168, 2615, 2002 (Featured article)

 

30. Jalkut MW, Reiter RE. Role of prostate stem cell antigen in prostate cancer research. Current Opinion in Urology. 12: 401, 2002

 

31. Tran C., Lin C, Yamashiro J and Reiter RE. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Molecular Cancer Research, 1: 113, 2002

 

32. Christiansen JJ, Rajasekaran SA, Moy P, Butch A, Goodglick L, Gu Z, Reiter  RE, Bander NH, Rajasekaran AK. Polarity of prostate specific membrane antigen, prostate stem cell antigen and prostate specific antigen in prostate tissue and in a cultured epithelial cell line. The Prostate, 55: 9, 2003

 

33. Freedland SJ, deGregorio F, Sacoolidge JC, Elshimali YI, Csathy GS, Dorey F, Reiter RE, Aronson WJ. Preoperative p27 status is an independent predictor of PSA failure following radical prostatectomy. Journal of Urology, 169: 1325,  2003

 

34. Cheng L, Reiter RE*,. Jin Y, Hirschowitz S, Weider J, Rao J (* corresponding author) Immunocytochemical analysis of prostate stem cell antigen as an adjunct marker for the detection of urothelial transitional cell carcinoma in voided urine specimens. Journal of Urology.  169:2094, 2003.

 

35. Freedland SJ, deGregorio F, Sacoolidge JC, Elshimali YI, Csathy GS, Elashoff DA, Reiter RE, and Aronson WJ. Predicting Biochemical Recurrence Following Radical Prostatectomy for Patients with Organ-Confined Disease Using p27 Expression. Urology: 61:1187, 2003.

 

36. Han KR, Seligson DB, Liu X, Horvath S, Shintaku PI, Thomas GV, Said JW, Reiter RE. Prostate stem cell antigen expression is associated with Gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. Journal of Urology. 171:1117, 2004

 

37. Garraway I, Said J, Seligson D, Reiter RE: Trefoil factor 3 is overexpressed in prostate cancer. The Prostate, 61:204, 2004

 

38. Thomas GV, Horvath S, Smith BL, Crosby K, Schrage M, Said J, deKernion JB, Reiter RE and Sawyers CL. Antibody based profiling of the PI3K pathways in clinical prostate cancer. Clinical Cancer Research, 10: 8351, 2004

 

39. Gu Z, Rubin  MA, Brooks JD, Loda M, Reiter RE. Reg 4 is overexpressed in hormone refractory, metastatic prostate cancers. Clinical Cancer Research, 11:2237, 2005

 

40. Lam J, Yamashiro J, Shintaku P, Vessella R, Jenkins R, Said J, Reiter RE. Prostate Stem Cell Antigen is Overexpressed in Prostate Cancer Metastases. Clinical Cancer Research, 11: 2591, 2005

 

41. MN. Wente, * A Jain * E Kono  PO. Berberat, T Giese, HA. Reber,  H Friess,  MW. Büchler,  RE. Reiter,  OJ. Hines, MD . Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas, 31:119-25, 2005

 

42. Chin J, Reiter RE. Molecular markers and prostate cancer prognosis. Clinical Prostate Cancer, 3:157, 2005

 

43. Gu Z, Yamashiro J, Kono E,. Reiter RE  Anti-Prostate Stem Cell Antigen Monoclonal Antibody 1G8 Induces Cell Death In vitro and Inhibits Tumor Growth In vivo via a Fc-Independent Mechanism. Cancer Res., 65:9495-500, 2005

 

44. Zemskova M, Wechter W, Baskkirova S, Chen CS, Reiter RE, Lilly ME. Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase. Biochem Pharmacol. August, 2006

 

45. Rao D, Gui D, Koski ME, Wang H, Popoviciu LM, Reiter RE, Said JW, An inverse relation between COX-2 and E-Cadherin expression correlates with aggressive histologic features in prostate cancer. Applied Immunohistochemistry and Molecular Morphology, 2006

 

46. Lam JS, Reiter RE Stem cells in prostate and prostate cancer development. Urological Oncology 24: 131-140, 2006

 

47. Olafsen T, Gu Z , Sherman MA, Leyton JV, Witkosky ME, Shively JE, Raubitschek AA, Morrison SL, Wu AM and Reiter RE. Targeting, Imaging, and Therapy using a Humanized Anti-Prostate Stem Cell Antigen (PSCA) Antibody. . J Immunother (1997). 2007 May-Jun;30(4):396-405.

 

48. Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR, Reiter RE . Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer. 2007 Jun 1;109(11):2239-47.

 

49.Lin K, Lee SP, Cho JS, Reiter RE, deMarco JJ. Solberg TD Improvements in prostate brachytherapy dosimetry due to seed stranding. Brachytherapy. 2007 Jan-Mar;6 (1):44-8.

 

50. Pariente N, Morizono K, Virk M, Petrigliano F, Reiter RE, Lieberman JR, Chen ISY. Systemic administration of a dual-targeted lentiviral vector leads to highly specific transduction of prostate cancer bone metastases in vivo. Molecular Therapy, Nov; 15(11): 1973-81,  2007

 

51. Moore ML, Teitell MA, Kim Y, Watabe T, Reiter RE, Witte ON, Dubey P Deletion of PSCA increases metastasis of TRAMP-induced prostate tumors without altering primary tumor formation.  Prostate, Feb 1;68:139-51, 2008

 

52. Gulati M, Raman S, Naini B, Thomas A, Lu D, Reiter RE. Utility of MRI/MRSI in planning robotically assisted laparoscopic radical prostatectomy: report of experience with histopathological correlation. In Press, Urology, 2008

 

53. Reiter RE, Riggs S: What factors affect the PSA relapse free survival times in patients treated with permanent seed brachyhterapy? Nature Clinical Practice urology. Dec; 4(12): 650. 2007

 

54: Reiter RE. Controversies in urologic oncology: Urologic Oncology. 25(6) 489. 2007

 

55. van de Poll-Franse LV, Kwan L, Reiter RE, Lee SP, Litwin MS The influence of cardiovascular disease on health related quality of life in men with prostate cancer: a four year followup study. Journal of Urology 2008

 

56. Hara T, Miyazaki H, Tran C, Reiter RE. Androgen receptor mediates invasiveness of prostate cancer cells. Cancer Research 68(4):1128-35, 2008

 

57. Van de Poll-Franse LV, Kwan L, Reiter RE, Lee SP, Litwin MS The influence of cardiovascular disease on health related quality of life in men with prostate cancer: a 4-year followup study. J Urol. 2008 Apr;179(4):1362-7; discussion 1367

 

58. Fondrevelle ME, Kantelip B, Reiter RE, Chopin DK, Thiery JP, Monnien F, Bittard H, Wallerand H. The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status. Urol Oncol. 2008 Apr 25

 

59. Leyton JV, Olafsen T, Lepin EJ, Hahm S, Bauer KB, Reiter RE, Wu AM. Humanized radioiodinated minibody for imaging of prostate stem cell antigen expressing tumors. Clinical Cancer Res 2008 14(22): 7488-96

 

60. Leyton JV, Olafsen R, Sherman MA, Bauer KB, Aghajanian P, Reiter RE, Wu AM. Engineered humanized diabodies for microPET imaging of prostate stem cell antigen expressing tumors. Protein Eng Des Sel 2009 22(3): 209-16

 

61. Wallerand H, Cai Y, Wainberg ZA, Garraway I, Lascombe I, Nicolle G, Thiery JP, Bittard H, Radvanyi F, Reiter RE  Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines. Urol Oncol. 2008 Dec 11

62. Wallerand H, Reiter RE, Ravaud A. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signaling pathways. Curr. Opinion Urology. 2008 18(5): 524-32

63. Shurtleff B, Rao J, Reiter RE. Prospective evaluation of PSCA immunocytology for the diagnosis of bladder cancer. Submitted, 2008

 

64. Garrway I, Tran C, Witte ON, Reiter RE. Human prostaspheres: initial characterization. In preparation, 2008

 

 

Chapters

 

1. Reiter RE, Zbar B, Linehan WM:  Molecular genetic studies of renal cell carcinoma: potential biologic and clinical significance for genitourinary malignancy.  In Walsh PC, Retik AB, Stamey TA, Vaughan ED (eds):  Campbell’s Urology (update 7), WB Saunders, Philadelphia, 1993

 

2. Reiter RE, Scardino PT, Miles B:  Salvage radical prostatectomy for local recurrence of prostate cancer after radiation therapy.  In Vogelzang N, Scardino PT, Shipley W, Coffey D (eds) Comprehensive Textbook of Genitourinary Oncology.  Williams and Wilkins, 1995/2000 (update)

 

3. Reiter RE and Sawyers CL: Xenograft models and the molecular biology of human prostate cancer. In Isaacs WB and Chung L (eds) Prostate Cancer, 2001.

 

4. Reiter RE and DeKernion JB: Epidemiology, Etiology and Prevention of Prostate Cancer. In Walsh PC, Retik AB, Stamey TA, Vaughan ED (eds): pgs. 3003-3024. Campbell’s Urology, WB Saunders, Philadelphia. 2002.

 

5. Chin J and Reiter RE Genetic Alterations in Prostate Cancer.  Current Urology Reports, 5: 157, 2004

 

6. Reiter RE and Kibel A, Molecular Biology of Urologic Cancer, Campbell’s Urology, 2006.

 

7. Lam J. and Reiter RE, Tissue Markers for Prostate Cancer, Comprehensive Prostate Cancer Textbook, 2006.

 

 

 

 

Scientific Editorials

 

1. Reiter RE: Editorial comment:The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients. Journal of Urology 158:1884, 1997

 

2. Reiter RE: Editorial comment: Adenocarcinoma of the urachus and bladder expresses a unique colonic epithelial epitope: an immunohistochemical study. Journal of Urology 158: 1722, 1997

 

3. Reiter RE: Editorial comment: Retrospective comparison of radical retropubic prostatectomy and I125 brachytherapy for localized prostate cancer. Journal of Urology 161:1215, 1999

 

4. Reiter RE: Editorial comment: Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy. Journal of Urology 161:1203, 1999

 

5. Reiter RE: Robotically assisted laparoscopic prostatectomy: getting started.  The Maerican Journal of Urology. 3: 1-4, 2005

 

6. Reiter RE, Shurtlef B What are the operating characteristics of PSA for screening prostate cancer? Nature Clinical Practice Urology. 2: 74-75, 2006

 

 

Published Abstracts

 

1. Gnarra JR, Latif F, Tory K, Anglard P, Reiter RE, Trahan E, Liu S, Lerman M, Zbar B, Linehan WM:  Molecular characterization of tumor suppressor genes involved in human renal cell carcinoma. Journal of Urology 147 Supplement: 319A, 1992

 

2. Reiter RE, Gnarra JR, Anglard P, Liu S, Linehan WM:  Chromosome 17p deletions and p53 mutations in advanced renal cell carcinoma. Journal of Urology 149 Supplement: 462A, 1993

 

3. Walther MM, Alexander RB, Reiter RE, Choyke PL, Linehan WM:  Nephron sparing surgery in patients with hereditary and sporadic renal cell carcinoma. Journal of Urology 151 Supplement: 317A, 1994

 

4. Reiter RE, Wheeler T, Carlton CE, Scardino PT, Miles BJ:  Radical perineal vs. retropubic prostatectomy in clinical T1c prostate cancer: a pathologic comparison.  Journal of Urology 153 Supplement: 501A, 1995

 

5. Reiter RE, Klein K, Sawyers C, Witte ON:  Representational difference analysis of human androgen-independent prostate cancer. American Association for Cancer Research Meeting Proceedings 37: 246, 1996

 

6. Klein K, Reiter RE, Belldegrun A, Sawyers C:  Development of a unique model for the propagation and study of human prostate tumors in vivo. American Association for Cancer Research Meeting Proceedings 37: 71, 1996

 

7. Walther MM, Reiter RE, Keiser HR, Choyke P, Zbar B, Linehan WM:  Pheochromocytoma in von Hippel-Lindau disease:  clinical and genetic characterization. Journal of Urology 155 Supplement: 499A, 1996

 

8. Reiter RE, Magi-Galuzzi C, Hemmatti H, Sawyers C, Loda M, Witte ON: Two genes upregulated in androgen-independent prostate cancer are also selectively expressed in the basal cells of normal prostate epithelium. Journal of Urology 157 Supplement: 269A, 1997

 

9. Redula J, Klein K, Reiter R, Witte ON, Sawyers C: Progression of human prostate cancer to androgen independence in immunodeficient SCID mice. American Association for Cancer Research Meeting Proceedings 38:  1997

 

10. Craft, N, Tran C, Chhor C, Stevenson S, Belldegrun A, Witte ON, Reiter RE, Sawyers CL: Metastatic and hormone dependent characteristics of the LAPC series of prostate cancer xenografts. American Association for Cancer Research Meeting Proceedings 39: 1998

 

11. Whang Y, Wu X, Tran C, Reiter RE, Vessella R, Sawyers C: Frequent transcriptional silencing of the tumor suppressor PTEN/MMAC1 gene in prostate cancer xenografts. American Association for Cancer Research Meeting Proceedings 39, 1998

 

12. Gu Z, Shintaku P, Yamashiro J, Said J, Reiter RE: Monoclonal antibodies against prostate stem cell antigen (PSCA) detect high levels of PSCA expression in prostate cancer bone metastases. Journal of Urology 161 Supplement 477A, 1999

 

13. Reiter RE, Yamashiro J, Sawyers C, Loda M, Witte ON: A type II transmembrane glycoprotein associated with osteogenesis can accelerate androgen-independent prostate cancer progression in vivo. Journal of Urology 161 Supplement 488A, 1999

 

14. Rauch M, Schrage M, Dorey F, deKernion JB, Said J, Reiter RE: Low p27 protein expression independently predicts poor disease free survival in patients with positive surgical margins following radical prostatectomy. Journal of Urology 161 Supplement 924A, 1999

 

15. Brandeis JM, Litwin MS, Nurnison CM, Reiter RE: Early quality of life outcomes in men receiving brachytherapy or radical prostatectomy. Journal of Urology 161 Supplement 1375A, 1999

 

16. Amara N, Gu Z, Salur G, Schrage M, Thomas G, Said J, Reiter RE: Prostate stem cell antigen (PSCA) is overexpressed in a majority of bladder cancers. European Urology 37 Supplement 2 354A, 2000

 

17. Amara N, Gu Z, Dorey F, Reiter RE: Monoclonal antibodies against prostate stem cell antigen inhibit prostate cancer tumor formation in SCID mice. European Urology 37 Supplement 2  420A, 2000

 

18. Brandeis J, Chand I, Kwan L, Dougherty S, Reiter RE, Litwin MS: Pretreatment quality of life in men with early stage prostate cancer. Journal of Urology 163 Supplement 68A, 2000.

 

19. Watabe T, Lin M, Donjacour A, Cunha G, Witte ON, Reiter RE: The 9kb prostate stem cell antigen promoter directs reporter gene expression to the ductal tips of prostate in transgenic mice. Journal of Urology 163 Supplement 132A, 2000

 

20. Amara N, Thomas G, Said J, Reiter RE: Prostate stem cell antigen is overexpressed in a majority of bladder cancers. Journal of Urology 163 Supplement 552A, 2000.

 

21. Thomas G, Schrage M, Dorey M, Said J, Reiter RE: Correlation of p27 expression in preoperative prostate needle biopsy and subsequent radical prostatectomy. Journal of Urology 163 Supplement 810A, 2000.

 

22. Brandeis J, Chand I, Kwan L, Dougherty S, Reiter RE, Litwin MS: A prospective study of the short term effects of radical prostatectomy vs. brachytherapy on quality of life. Journal of Urology 163 Supplement 1267, 2000.

 

23. Palapattu G, Gu Z, Saffran D, Kono E, Yamshiro J, Jakobovits A, Reiter RE. Monoclonal antibody against prostate stem cell antigen inhibits prostate cancer growth and metastasis in a murine xenograft  model of prostate cancer. Journal of Urology 165 Supplement 188A, 2001.

 

24. Palapattu G, Amara N, Gu Z, Thomas G, Yamashiro J, Dorey F, Said J, Reiter RE: Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Journal of Urology 165 Supplement 457A, 2001.

 

25. Tran C, Lin C, Yamashiro J, Reiter RE: Prostate stem cell antigen is  marker of an intermediate progenitor cell population in human prostate epithelial cells. Journal of Urology 165 Supplement 578A, 2001.

 

26. DePrimo S, Brown P, Brooks JD, Nelson JB, Reiter RE: Microarray analysis of the transcriptional programs activated by exposure of prostate cancer cells to androgen. Journal of Urology 165 Supplement 583A, 2001.

 

27. Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A. Anti-PSCA monoclonal antibodies inhibit tumor growth and prolong survival of mice bearing human prostate cancer xenografts. American Association of Cancer Research 4543A, 42, 2001

 

28. Litwin MS, Brandeis J, Chand I, Kwan L, Dougherty S, Reiter RE. Quality of life in the year following brachytherapy, external beam radiation or prostatectomy. Journal of Urology 167 Supplement 122A, 2002

 

29. Jain A, Carey M, Reiter RE. A tissue specific enhancer directes the androgen responsive regulation of prostate stem cell antigen.  Journal of Urology 167 Supplement 122A, 2002

 

30. Gu Z, Yamashiro J, Kono E, Reiter RE. A monoclonal antibody against PSCA inhibits prostate cancer growth and metastasis through a direct effect of tumor cells. Journal of Urology 169 Supplement 348A, 2003

 

31. Reiter RE, Seligson D, Said J. Trefoil factor 3 is overexpressed in prostate cancer. Journal of Urology 169 Supplment 643A, 2003

 

32. Garraway IP, Tran C, Reiter RE. Development of a novel mouse model for induction and imaging of bladder cancer. Journal of Urology 169  Supplement 735A, 2003

 

33.   Freedland S, Degregorio F, Csathy GC, Dorey F, Reiter RE, Aronson WJ. Preoperative p27 status is an independent predictor of PSA failure following radical prostatectomy. Journal of Urology Supplement 169:  1851A, 2003

 

34. Reiter RE, Rubin M, Loda M, Gu Z. Reg IV. A promising marker of hormone refractory metastatic prostate cancer. Journal of Urology Supplement 171: 590A, 2004

 

35. Han K, Seligson D, Liu X, Horvath S, Shintaku PI, Thomas G, Said JW, Reiter RE. Prostate stem cell antigen expression is associated with Gleason score, seminal vesical invasion and capsular invasion in prostate cancer. Journal of Urology Supplement 171: 860A, 2004

 

36. Reiter Re, Wu A, Sherman M, Gu Z  Recombinant anti-PSCA antibodies inhibit prostate and bladder cancer growth in xenograft models and are superior to parental murine antibody. Journal of urology Supplement 171: 1091A, 2004.

 

Patents

 

1. CL Sawyers, ON Witte, RE Reiter, K Klein: Animal models of prostate cancer, #6,107,540 2000

2. RE Reiter and ON Witte: E25 Protein, methods for Producing and Using, US# 7,030,232, 2006

3. RE Reiter and ON Witte: PSCA Monoclonal Antibodies and Hybridomas, #6,258,939, 2001

4. RE Reiter: PSCA-Prostate stem cell antigen, #6,267,960, 2001

5. RE Reiter and ON Witte. Method for diagnosing cancer using specific PSCA antibodies, #6,261,791, 2001

6. RE Reiter and ON Witte. Methods for detecting the presence of a PSCA protein using PSCA antibodies. #6,261,789, 2001

7.  RE Reiter, ON Witte, DS Saffran, A Jakobovitz. PSCA: prostate stem cell antigen and uses thereof. International Patent # WO 01-005427  A1

8. RE Reiter and ON Witte. Methods for detecting prostate stem cell antigen protein. #6,541,212, 2003

9. RE Reiter and ON Witte. Methods for treating cancer using PSCA antibodies and fragments thereof. #6,756,036. 2004

10. RE Reiter, ON Witte, DS Saffran, A Jakobovitz. Nucleic acids encoding prostate stem cell antigen. US 6,979,730. 2005

 

Clinical Trials

 

1. Principal Investigator. Subcutaneous vs. High Dose Bolus IL-2 For Metastatic Renal Cell Carcinoma. Baylor College of Medicine, Houston, TX, 1994-1995

 

2. Co-Investigator. Anti-Epidermal Growth Factor Receptor Antibody For Metastatic  Renal and Prostate Cancers. Abgenix Corporation. 2000-2001

 

3. Co-Investigator. Randomized Prospective Study of Adjuvant Androgen Ablation In Radical Prostatectomy Patients at High-Risk For Disease Recurrence. Tap Pharmaceuticals. 1999

 

4. Co-Investigator. Phase III Randomized Double-Blinded Study of DFMO vs. Placebo in Low Grade Superficial Bladder Cancer. NCI, University of Wisonsin, ILEX Pharmaceuticals. 1999

 

5. Principal Investigator. A Phase III, Randomized, Double-Blinded, Placebo Controlled Study of the Safety and Efficacy of 10mg Atrasantan in Men with Metastatic, Hormone Refractory Prostate Cancer. Abbot Pharmaceuticals. 2001-

 

6. Principal Investigator. A Phase III, Randomized, Double-Blinded, Placebo Controlled Study of the Saftey and Efficiacy of 10mg Atransantan in Men with Nonmetastatic, PSA-only Hormone Refractory Prostate Cancer. Abbot Pharmaceuticals. 2001-

 

7. Principal Investigator. .A Phase I/II Translational Study of Neoadjuvant Rapamycin Analogue CCI-779 in Patient siwht High Risk Prostate Cancer. Wyeth Ayerst and Prostate SPORE, 2003 -

 

 

 

Invited Lectures, Visiting Professorships and Presentations

 

 

1. Evaluation of p53 mutations in human renal cell carcinoma. Society for Basic Urologic Research. Annual Meeting. Washington, DC, May 1992

 

2. Chromosome 17p deletions and p53 mutations in advanced renal cell carcinoma. American Urological Association.  Annual Meeting. San Antonio, TX, May 1993

 

3. The role of the nm23 tumor suppressor gene in prostate cancer.  Baylor College of Medicince. First Annual Matsunaga-Conti Symposium on Prostate Cancer. Houston, TX, May 1993

 

4.  Transfection of the human nm23-H1 gene into the human prostate carcinoma cell line PC3: effects on tumorigenicity and metastatic potential.  American Association for Cancer Research:  Special Conference on the Molecular Genetics of Tumor Progression and Metastasis, Big Sky, MT, February 1994

 

5. Radical perineal vs. retropubic prostatectomy in clinical T1c prostate cancer: a pathologic comparison.  American Urological Association. Annual Meeting. Las Vegas, NV, April 1995

 

6. Representational difference analysis of human androgen-independent prostate cancer. American Association for Cancer Research. Annual Meeting. Washington, DC, April 1996

 

7.  Pheochromocytoma in von-Hippel Lindau disease.UCLA Department of Surgery. Grand Rounds. April 5, 1996.

 

8.  Differential gene expression in androgen-independent prostate cancer.UCLA Molecular Biology Institute. Annual Retreat. October, 1996.

 

9. Markers of androgen-independent prostate cancer.Jonsson Comprehensive Cancer Center. Cancer Center Basic Science Conference. November 6, 1996.

 

10.Prostate cancer update. UCLA Continuing Medical Education. Current Topics in Primary Care. December 14, 1996.

 

11. New animal models for the study of prostate cancer. Jonsson Comprehensive Cancer Center. Prostate Cancer Program Retreat. January 17, 1996.

 

12. Urinary tract infections: an update. UCLA Continuing Medical Education. Current Topics in Primary Care. January 21, 1997.

 

13. Update on tumor markers for carcinoma in situ in superficial bladder cancer. State of the Art Conference., UCLA Department of Urology. Marina del Rey, February 8, 1997

 

14. Two genes upregulated in androgen-independent prostate cancer are also selectively expressed in the basal cells of normal prostate epithelium. American Urological Association. Annual Meeting. New Orleans, Louisiana, April 1997

 

15. A new animal model to study prostate cancer. Invited Lecture, Department of Urology, Hadassah Hospital, Jerusalem, Israel. June 22, 1997

 

16. Prostate cancer update.UCLA Continuing Medical Education. Current Topics in Primary Care. July 18, 1997.

 

17. Prostate cancer update.UCLA Continuing Medical Education. Current Topics in Primary Care. July 21, 1997.

 

18. Novel markers of androgen-independent prostate cancer. CaP CURE. Annual Retreat. Incline Village, Lake Tahoe, Nevada, September 1997

 

19.Urinary Diversions: The UCLA Experience. State of the Art Conference. UCLA Department of Urology. Marina del Rey. February, 1998.

 

20. Prostate Cancer Screening: Why It’s A Good Thing.  Controversies in Prostate Cancer. Rancho Mirage, CA.  March 27-28, 1998.

 

21. Early Detection of Prostate Cancer. UCLA Continuing Medical Education. Primary Care Conference. Las Vegas, NV. April 4, 1998.

 

22. Prostate Cancer Update  UCLA Continuing Medical Education . 50+ Patient Education Conference UCLA .April 24, 1998

 

23. Prostate Cancer Update  Harbor-UCLA Medical Center Grand Rounds. May 1, 1998

 

24.  Prostate Stem Cell Antigen, a Potential New Target in Prostate Cancer  UCLA Cancer Center Research Conference. June 11,1998

 

25. Renal cell carcinoma genetics. 17th Annual Meeting of the Venezuelan Association of Urology. Caracas Hilton, Caracas, Venezuela, July 26, 1998

 

26. Partial vs. radical nephrectomy in the management of renal cell carcinoma. 17th Annual Meeting of the Venezuelan Association of Urology. Caracas Hilton, Caracas, Venezuela, July 26, 1998

 

27.  Gene and immunotherapy in renal cell carcinoma. 17th Annual Meeting of the Venezuelan Association of Urology. Caracas Hilton, Caracas, Venezuela, July 26, 1998

 

28. Prostate Stem Cell Antigen: a novel cell surface antigen expressed by prostate cancer. CaP CURE Annual Retreat. Incline Village, Lake Tahoe, Nevada, September, 1998

 

29.  Surgical management of localized prostate cancer. National Visiting Professor Academy Symposium on Quality of Life Issues in Prostate Cancer Management.  Cancun, Mexico. September, 1998

 

30.  Low p27 expression predicts poor disease-free survival in patients with prostate cancer. AUA Western Section. Hilton Waikoloa, Big Island, Hawaii. October, 1998

 

31. Prostate stem cell antigen (PSCA), a novel prostate-specific cell surface

protein, is expressed in a majority of prostate cancers. AUA Western Section. Hilton Waikoloa, Big Island, Hawaii. October, 1998

 

32. Prostate Cancer: What's New in the Clinic and in the Laboratory UCLA Business Executives Program. October 8, 1998

 

33. Prostate Stem Cell Antigen  UCLA Jonsson Cancer Center Prostate Program Retreat. November 16, 1998 

 

34. PSCA in prostate cancer biology. AACR Special Conference on "New Research Approaches in the Prevention and Cure of Prostate Cancer". Hyatt Grand Champions Resort, Indian Wells, CA. December, 1998

 

35. Prostate Cancer Tumor Markers.  State of the Art Urology Conference. UCLA Department of Urology. Marina del Rey. February 14-15, 1999

 

36. Quality of Life After Surgery and Brachytherapy. State of the Art Urology Conference. UCLA Department of Urology . Marina del Rey. February 14-15, 1999

 

37.  New Advances in the Lab and Clinic for Prostate Cancer. Fullerton Prostate Cancer Forum.February 24, 1999

 

38. BPH and Prostate Cancer Update. UCLA Continuing Eductaion Series, February 26, 1999

 

39. Prostate stem cell antigen: a potential target for monoclonal antibody based immunotherapy of prostate cancer. City of Hope Cancer Center, Duarte, CA. March 11, 1999

 

40. Quality of life after brahcytherapy for localized prostate cancer. Los Angeles Urological Society, Anaheim, Ca. March 23, 1999

 

41. Monoclonal antibodies against PSCA detect high levels of expression in prostate cancer bone metastases .Amgen Corporation, Thousand Oaks, CA.  March 25, 1999

 

42. Prostate Cancer Screening: Does it work and should it be recommended? Harvard-UCLA Conference in Primary Care. Long Beach, Ca. April 9, 1999

 

43. Prostate Stem Cell Antigen.  Visiting Professor. Urological Oncology Branch, National Cancer Institute, Bethesda, Md.  May 13, 1999

 

44. The 9kb human PSCA  Promoter Directs Reporter Gene Expression to the Ductal Tips of Prostate in Transgenic Mice. Gordon Research Conference, New Hampshire, August 10,1999

 

45.Quality of Life After Prostate Brachytherapy. Postgraduate Course on Brachytherapy, Western Section, American Urological Association, Monterey, California. September 27, 1999.

 

46. Prostate Stem Cell Antigen: a Potential Target for Prostate Cancer Diagnosis and Therapy. CaP CURE Annual Retreat. Incline Village, Lake Tahoe, Nevada, October 14-17, 1999

 

47. Prostate Stem Cell Antigen: Utilities for the Study of Normal and Malignant Prostate Biology. Visiting Professor. Dana Farber Cancer Center. Boston, Mass. October 26, 1999

 

48. Molecular Imaging Using the Prostate Stem Cell Antigen Promoter. Jonsson Comprehensive  Cancer Center Translational Research Conference. UCLA. January 27, 2000

 

49. Prostate Stem Cell Antigen in Prostate Cancer. Visiting Professor. Memorial Sloan Kettering Cancer Center. New York, NY. February 4,  2000

 

50. Prostate Cancer Brachytherapy: Overview and Comparison with Radical Prostatectomy. Venezuelan Congress on Urologic Oncology. Caracas, Venezuela.  February 24-27, 2000.

 

51. Quality of Life After Prostate Brachytherapy. Venezuelan Congress on Urologic Oncology. Caracas, Venezuela.  February 24-27, 2000.

 

52. Novel Molecular Markers in Bladder Cancer.  Venezuelan Congress on Urologic Oncology. Caracas, Venezuela.  February 24-27, 2000.

 

53. Practical Course in Prostate Brachytherapy (Taller de Braquiterapia).  Venezuelan Congress on Urologic Oncology. Caracas, Venezuela.  February 24-27, 2000.

 

54. Issues and Strategies in Prostate Cancer Diagnosis. UCLA State of the Art in Urology Conference. Marina Del Rey, California.  March 3-4, 2000.

 

55. p27: A  Potential Molecular Marker in Prostate Cancer. Prostate Cancer Charitable Trust Biannual Conference. Bethesda, Maryland. March 10-12, 2000.

 

56. Renal Cell Carcinoma: Update. Biannual Brazillian Congress on Urologic Oncology. Sao Paulo, Brazil. March 31-April 2, 2000.

 

57. Novel Moelcular Markers in Bladder Cancer. Biannual Brazillian Congress on Urologic Oncology. Sao Paulo, Brazil. March 31-April 2, 2000.

 

58. Gene Therapy and Adjuvant Therapy for Renal Cell Carcinoma. Biannual Brazillian Congress on Urologic Oncology. Sao Paulo, Brazil. March 31-April 2, 2000.

 

59. Second Look TURBT For Bladder Cancer. Biannual Brazillian Congress on Urologic Oncology. Sao Paulo, Brazil. March 31-April 2, 2000.

 

60. Total Androgen Blockade: Should it be Abandoned? Biannual Brazillian Congress on Urologic Oncology. Sao Paulo, Brazil. March 31-April 2, 2000.

 

61. Second Tumors After Treatment for Testicular Cancer. Biannual Brazillian Congress on Urologic Oncology. Sao Paulo, Brazil. March 31-April 2, 2000.

 

62. TURP After Negative Biopsies: Are They Indicated? Biannual Brazillian Congress on Urologic Oncology. Sao Paulo, Brazil. March 31-April 2, 2000.

 

63. Prostate Stem Cell Antigen (PSCA): A Novel Cell Surface Antigen in Prostate Cancer. American Urological Association/ European Association of Urology Academic Exchange Program. Strasbourg, France; London, England; Prague, Czech Republic, Hamburg, Germany; Brussels, Belgium. April 8-April 26, 2000 (Seminar given at each institution).

 

64. P27: A New Molecular Marker in Prostate Cancer. American Urological Association/ European Association of Urology Academic Exchange Program. Strasbourg, France; London, England; Prague, Czech Republic, Hamburg, Germany; Brussels, Belgium. April 8-April 26, 2000 (Seminar given at each instittution).

 

65. Brachytherapy for the Treatment of Localized Prostate Cancer: Pros and Cons. Joint Meeting of the American Urological Association (AUA) and the Central American and South American Urological Association (CAU). Annual Meeting of the AUA, Atlanta, Georgia, April 29, 2000. (In Spanish)

 

66. Update on Results and Quality of Life After Prostate Brachytherapy. Urology Grand Rounds. Harbor-UCLA Medical Center, Torrance, CA. June 1, 2000

 

67. The PSCA Promoter Directs Transgene Expression to a Putative Prostate Epithelial Progenitor Cell Population in a Transgenic Mouse Model. NIH Mouse Models Consortium Conference, Washington, D.C. , July 8-9, 2000

 

68. Xenograft Models of Prostate Cancer for Translational Research. The Example of Prostate Stem Cell Antigen (PSCA). American Urological Association Special  Conference on Mouse Models of Prostate Cancer. Houston, Texas, August 4-6

 

69. Prostate Stem and Progenitor Cells. NIDDK/NIA Joint Symposium of the Prostate and Aging. Washington, D.C.  September 13-15, 2000  

 

70. Prostate Stem Cell Antigen: a Promising Target for Prostate Cancer Therapy. CapCURE,

Incline Village, Nevada, September 21-24, 2000 

 

71. Update on Brachytherapy.  Ecuadorean Association of  Urology, Quito, Ecuador, November 22-24, 2000 (In Spanish)

 

72. Advances in the Molecular Biology of Prostate Cancer.  Ecuadorean Association of  Urology, Quito, Ecuador, November 22-24, 2000 (In Spanish)

 

73. Bladder Cancer Markers.  Ecuadorean Association of  Urology, Quito, Ecuador, November 22-24, 2000 (In Spanish)

 

74. New Treatments for Advanced Prostate Cancer.  Ecuadorean Association of  Urology, Quito, Ecuador, November 22-24, 2000 (In Spanish)

 

75. Quality of Life After Brachytherapy and Surgery for Localized Prostate Cancer.  Ecuadorean Association of  Urology, Quito, Ecuador, November 22-24, 2000 (In Spanish)

 

76. Prostate Stem Cell Antigen: A Promising Target for Prostate Cancer Diagnosis and Therapy. Visiting Professor. Department of Urology, University of Miami, Miami, Fla. January 11, 2001

 

77. Molecular Biology, Targeted Therapy and the Future of Prostate Cancer Diagnostics and Therapeutics. State of the Art Urology Conference, UCLA School of Medicine, Marina del Rey, CA February, 2001

 

78. Prostate Cancer Brachytherapy and Quality of Life Compared to Radical Prostatectomy. Czech Republic Symposium of Urology. First Department of Urology. Charles University. Prague, Czech Republic, March, 2001.

 

79. Prostate Stem Cell Antigen: a Promising Therapeutic Target in Prostate Cancer. Visiting Professor. UT Southwestern School of Medicine. Dallas, Texas, May, 2001

 

80. Prostate Stem Cell Antigen: a Promising Therapeutic Target in Prostate Cancer. John Wayne Cancer Institute,  July, 2001

 

81. Prostate Stem Cell Antigen Monoclonal Antibodies Inhibit Prostate Cancer Growth By a Direct, Fc Independent Mechanism. Annual CaP CURE Meeting, Incline Village, NV. September, 2001

 

82. The Use of the PSCA Promoter For Creation of Transgenic Models of Prostate Cancer. Jackson Lab Conference on Transgenic Models of Prostate Cancer. Sponsored by the National Cancer Institute. Bar Harbor, Maine. October ,2001

 

83. Prostate Cancer State of the Art. Annual Meeting of the Central Society of Japanese urology. Osaka, Japan. November, 2001

 

84. Prostate Cancer Potpourri: Quality of Life and Molecular Markers. Grand Rounds. Cedars Sinai Hospital, Los Angeles, CA. December, 2001

 

85. Prostate Stem cell Antigen: Recent Observations. Prostate Cancer Program. UCLA School of Medicine, January 15, 2002

 

86. Prostate Cancer Update. Israel Cancer Research Fund. Los Angeles, CA. January 16, 2002

 

87. p27 and PSCA as Molecular Markers and Targets in Prostate Cancer. Visiting Professor. Cornell Universty Medical School. Department of Urology. January 28, 2002

 

88. Prostate Stem Cell Antigen Monoclonal Antibodies Inhibit Prostate Cancer Growth By a Direct, Fc- Independent Mechanism. Innovators in Urology Meeting. Miami, Florida. March, 2002

 

89. Chemotherapy in Bladder Cancer. Joint Meeting of the American Urological Association (AUA) and the Central American and South American Urological Association (CAU). Annual Meeting of the AUA, Orlando, Florida, May, 2002.

 

90. Prostate Cancer Update. Ted Mann Center. Jonsson Comprehensive Cancer Center. UCLA. June 15, 2002

 

91. PSCA Monoclonal Antibody Therapy. Prostate Cancer Charitable Trust Biannual Think Tank. Oxford, England. June 20-24, 2002

 

92. Prostate Stem Cell Antigen is a Marker of Late Intermediate Prostate Epithelial Cells. Annual CaP CURE Meeting, Washington, D.C.. September 22, 2002

 

93. Prostate Stem Cell Antigen as Therapeutic Target. City of Hope Antibody Working Group. Duarte, CA October 15, 2002

 

94. Prostate Stem Cell Antigen as Therapeutic Target in Bladder, Prostate and Pancreatic Cancer. Medical Grand Rounds. City of Hope Cancer Center, Duarte, CA. November 12,2002

 

95. Prostate SPORE at UCLA. Jonsson Cancer Center Research Foundation. Los Angeles, CA. November 14, 2002

 

96. Prosate Stem Cell  Antigen as Potential Therapeutic Target in Prostate Cancer. Annual  Inter-SPORE Meeting. San Francisco, CA. December 3-4, 2002

 

97. Prostate Cancer Update, 2003. Tarzana Regional Medical Center, Tarzana, CA May 13, 2003

 

98. Identity of the Cell Type of Origin of Prostate Cancer: Possibilities. Innovators in Urology. Amsterdam, the Netherlands, June 3-5, 2003

 

99. Molecular Endpoints for Prostate Cancer Clinical Trials. Innovators in Urology Annual Meeting, Amsterdam, the Netherlands, June 3-5, 2003

 

100. A neoadjuvant study of CCI-779 in high risk prostate cancer patients prior to radical prostatectomy. Annual SPORE Meeting. Baltimore, MD. July , 2003

 

101. p27: a promising prognostic marker and therapeutic target in prostate cancer. Annual SPORE Meeting. Baltimore, MD. July, 2003

 

102. PSCA inhibits tumor growth through and Fc independent pathway. American Cancer Society Meet the Professors Meeting. Key Biscayne, Florida, October, 2003

 

103. Prostate cancer molecular targets. Society for Urologic Oncology. Annual Meeting. Bethesda, MD  December, 2003

 

104. PSCA: from bench to bedside. UCLA Prostate SPORE Lecture Series. January 20, 2004

 

105. PSCA: from bench to bedside. City of Hope Antibody Program. February 16, 2004

 

106. Neoadjuvant CCI-779 prior to radical prostatectomy in high-risk prostate cancer. Society of Urological Oncology Annual Meeting. San Francisco, CA May 10, 2004

 

107. Prostate cancer in 2004 (in Spanish). Guatemala Urological Association. Guatemala City, June 15, 2004

 

108. Prostate cancer in 2004 (in Spanish). El Salvador Urological Association. San Salvador, El Salvador, June 17, 2004

 

109. Definition of high-risk prostate cancer. Current debates in prostate cancer: integrating emerging therapies. Los Angeles. September 11, 2004

 

110. Prostate stem cell antigen: a lesson in translational science. Visiting Professor. University of Pittsburgh, Pittsburgh, PA Novermber, 2004

 

111. Hormonal therapy: integration with radiation, brachytherapy and surgery for prostate cancer(in Spanish). Controversies in Local Prostate Cancer. Hospital 11 Octubre. Madrid, Spain. November 24-25, 2004

 

112. Molecular targets in prostate cancer. Society for Urologic Oncology Annual Meeting. Washington, D.C. December 2-3, 2004

 

113. Photoselective vaporization of the prostate: A cost effective and clinically effective treatment for BPH. Kimbraugh Meeting, January, 2005

 

114. Reg IV: a promising marker for serum detection of hormone refractory prostate cancer. SPORE intraprostate meeting. Houston, TX January, 2005

 

115. Targeting mTOR in prostate cancer. ASCO/SUO Prostate Cancer Conference. Orlando, Fla. February, 2005

 

116. Imaging advances in prostate cancer. UCLA State of the Art Meeting. Marina del Rey, CA March, 2005

 

117. Prostate cancer update. UCLA Primary Care Conference. Las Vegas, NV. March, 2005

 

118. BPH update. UCLA Primary Care Conference. Las Vegas, NV. March, 2005

 

119. PSCA: target for prostate cancer therapy. Baylor College of Medicine, Prostate Cancer Conference, Houston, TX

 

120. Neoadjuvant studies targeting the mTOR pathways in prostate cancer. Baylor College of Medicine, Grand Rounds in Urology, Houston, TX

 

121. Photosective vaporization of the prostate. UCLA PVP Workshop, March and July, 2005

 

122. Photoselective vaporization of the prostate. Hong Kong Urological Association, Hong Kong, China. July, 2005

 

123. Targeted therapies in prostate cancer. Plenary Session. Western Section of the American Urological Association, Annual Meeting, Vancouver, CA August, 2005

 

124. Translational opportunities in bladder cancer research and care. Plenary Session. Eastern Section of the Japanese Urological Association. Iwate, Japan, September, 2005

 

125. Epithelial to mesenchymal transition in urological cancers. UCLA Genitourinary Research Conference. October, 2005

 

126. PVP vs Holmium laser prostatectomy. USA Endourology Meeting. San Francisco, CA November, 2005

 

127. PSCA—from bench to bedside: Annual Society for Urological Oncology Winter Meeting. Washington, D.C. Bethesda, MD. December, 2005

 

128. Prostate cancer stem cells. Society for Urological Oncology Spring Meeting. Atlanta, Ga. May, 2006

 

129. PSCA antibody therapy. From bench to bedside. Sixth International Conference on Monoclonal Antibodies in Cancer. Washington, D.C. August, 2006

 

130. Molecular approaches to prostate cancer. Puigvert Urology Conference. Barcelona, Spain, October, 2006

 

131. Targeted therapies in prostate cancer. International Society of Urological Oncology. Annual SIU meeting, Cape Town, South Africa, November, 2006

 

132. Economic costs of PVP. Society of International Urology. Cape Town, South Africa, November, 2006

 

133.  Robotic prostatectomy. UCLA State of the Art. Marina del Rey, March, 2007

 

134. Laser therapy of BPH. UCLA State of the Art. Marina del Rey, March, 2007

 

135. Robotic prostatectomy update. National Institute of Cancer Hospital. Beijing, China July, 2007

 

136. PSCA, a new target for prostate cancer therapy. National Institute of Cancer Hospital, Beijing, China, July 2007

 

137. PSCA: update on Phase I clinical trial of AGS-PSCA. Prostate Cancer Update. Bal Harbour, Florida, 2007

 

138. PSCA antibody therapy-- update on Phase I clinical trial of AGS-PSCA.. Eight International Conference on Monoclonal Antibodies in Cancer. Quebec City, Canada August, 2007

 

139. Robotic prostatectomy: tricks of the trade: Annual Meeting of the Mexican Society of Urological Oncology, Acapulco, Mexico, August, 2007

 

140: Molecular biology of prostate cancer: Annual Meeting of the Mexican Society of Urological Oncology, Acapulco, Mexico, August, 2007

 

141: Update on the use of targeted therapies in prostate cancer: Annual Meeting of the Mexican Society of Urological Oncology, Acapulco, Mexico, August, 2007

 

142: MRI and MRS staging of prostate cancer prior to robotic prostatectomy: International Society of Urological Oncology. Annual SIU meeting, Paris, France, September, 2007

 

143: PSCA: from bench to bedside: Visiting Professor, NYU Department of Urology, December, 2007

 

144: Imaging PSCA in prostate cancer: Department of Defense Investigator’s Meeting. Atlanta, Georgia, September, 2007

 

145: Epithelial to mesenchymal transition in prostate cancer: GU leaders in the field seminar. UCLA, January, 2008

 

146: Epithelial to mesenchymal transition in prostate cancer: Visiting Scientist, Takeda Corporation, Tsukuba, Japan, March 2008

 

147: Prostate cancer update: robotics, molecular biology, new therapies: Association of Mexican Urology Annual Meeting. Monterrey, Mexico, April, 2008

 

148: PSCA in prostate cancer: American Association for Cancer Research Annual Meeting, San Diego, CA April 2008

 

149. Imaging PSCA in prostate and other epithelial malignancies: Monoclonal Antibodies in Cancer. Dublin, Ireland, July, 2008

 

 

 

 

 

 





Not logged in | Log In